Top 3 Clinical Trial Specimen Shipping Concerns
QuickSTAT provides insight into protecting specimen integrity, advisory communications, and cost regarding specimen shipping.
Please note: We inadvertently directed to the wrong web site for Quickstat; the correct url is below.
QuickSTAT, a shipping and logistics company specializing in time and temperature critical transportation for the pharmaceutical and biotech industry gave LabViews the following insight into shipping lab specimens for clinical trials: 1) Protecting specimen integrity, 2) Advisory communications, 3) Cost. Dan Catizone, VP of Business Development for QuickSTAT, offered that many of these samples are transported under frozen conditions on dry ice and need to have temperature consistently controlled to maintain sample viability from pick up to arrival at the end destination.
"If the delivery deadlines are effected due to flight delays, customs issues, etc., dry ice is checked and replenished. QuickSTAT also provides advisory commuications to the investigator site, sponsor and receiving laboratory so that everyone is aware when delays occur.” With this specialized service, comes higher costs and decisions. "We may be more expensive than an intergrated courier (FedEx, UPS, etc). However, the sponsor typically will weigh their risks when choosing between our service and the integrator service based on prior experience or where the site origins and lab destinations are located for the trial.”
The financial implications and delay to the clinical trial if a sample is lost or perishes in transit typically outweigh the cost of the shipping. Catizone said QuickSTAT's services are predominantly used for international trials. However, QuickSTAT has seen an increase in the number of domestic trials they are awarded. QuickSTAT also offers annual Life Science training seminars that focus on the regulations governing how these samples must be shipped by air. The company is considering adding an import regulations component to these seminars which commence in the fall. Click here to visit the company web site: www.qicstat.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
